Press release
United Therapeutics Corporation Reports Record Third Quarter 2025 Financial Results
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today
About this update from United Therapeutics Corporation
[{"type":"text","content":" SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--\nUnited Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced record financial results for the quarter ended September 30, 2025, driven by continued year-over-year revenue growth in key products such as Tyvaso® and Orenitram®. Total revenues in the third quarter of 2025 grew seven percent year-over-year to $799.5 million, compared to $748.9 million in the third quarter of 2024.\n\n\n\"Our commercial and clinical teams continue to deliver record results, validating our strategic objectives,\" said Martine Rothblatt, Chairperson and Chief Executive Officer of United Therapeutics. \"The breakthrough results from our TETON-2 study in idiopathic pulmonary fibrosis could significantly broaden our therapeutic reach and accelerate our growth.\"\n\n\nMichael Benkowitz, President and Chief Operating Officer of United Therapeutics, added, \"This quarter we again achieved record total revenue and continued our double-digit growth for Tyvaso, reflecting a clear indication of the growing demand for our products. With laser focus and fierce determination, we are confident in our ability to sustain our growth trajectory.\"\n\n\nThird Quarter 2025 Financial Results\n\n\nKey financial highlights include (dollars in millions, except per share data):\n\n\n\n\n \n\n\n\n\n\n\nThree Months Ended\n\n\n\n\nSeptember 30,\n\n\n\n\n\n\n \n\n\n\n\n\n\nDollar\n\n\n\n\n\n\n \n\n\n\n\n\n\nPercentage\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n2025\n\n\n\n\n\n\n \n\n\n\n\n\n\n2024\n\n\n\n\n\n\n \n\n\n\n\n\n\nChange\n\n\n\n\n\n\n \n\n\n\n\n\n\nChange\n\n\n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n \n\n\n\n\n\n\n\n\nTotal revenues\n\n\n\n\n\n\n$\n\n\n\n\n\n\n799.5\n\n\n\n\n\n\n \n\n\n\n\n\n\n$\n\n\n\n\n\n\n748.9\n\n\n\n\n\n\n \n\n\n\n\n\n\n$\n\n\n\n\n\n\n50.6\n\n\n\n\n\n\n \n\n\n\n\n\n\n7\n\n\n\n\n\n\n%\n\n\n\n\n\n\n\n\nNet income\n\n\n\n\n\n\n$\n\n\n\n\n\n\n338.7\n\n\n\n\n\n\n \n\n\n\n\n\n\n$\n\n\n\n\n\n\n309.1\n\n\n\n\n\n\n \n\n\n\n\n\n\n$\n\n\n\n\n\n\n29.6\n\n\n\n\n\n\n \n\n\n\n\n\n\n10\n\n\n\n\n\n\n%\n\n\n\n\n\n\n\n\nNet income, per basic share\n\n\n\n\n\n\n$\n\n\n\n\n\n\n7.73\n\n\n\n\n\n\n \n\n\n\n\n\n\n$\n\n\n\n\n\n\n6.93\n\n\n\n\n\n\n \n\n\n\n\n\n\n$\n\n\n\n\n\n\n0.80\n\n\n\n\n\n\n \n\n\n\n\n\...